Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > ORGANIZATION
ORGANIZATION
- “No Need to Step Down” as Chair of Biz Lobby, Govt Panel Member: Takeda CEO
July 2, 2014
- Yokokura Reelected as JMA President, 3 Incumbents Retain Veep Seats
July 2, 2014
- Research-Driven Pharmas Could Diverge into 2 Groups Based on Dependence on Off-Patent Drugs: FPMAJ Chair
July 1, 2014
- Min-Iren Urges Novartis to Return “Unfair Profits”
June 24, 2014
- JMA President Yokokura to Serve Second Term
June 20, 2014
- Japan Diabetes Group Announces Recommendations on Proper Use of SGLT-2 Inhibitors
June 17, 2014
- Daiichi Sankyo Pres. Nakayama Elected as New President of PMAT
June 17, 2014
- New Price Cut Rule Barring Generic Replacement of Long-Listed Products: FPMAJ
June 17, 2014
- US-Japan Business Council Airs Concerns over Annual NHI Price Revision
June 13, 2014
- Member Companies Conducted 682 Clinical Trials in Japan in 2013: PhRMA/EFPIA
June 11, 2014
- Generic Versions of Combination Drug Exforge to Be Named “Amvalo”: JSGM
June 10, 2014
- Santen President Officially Becomes New OPMA Head
May 29, 2014
- FPMAJ, JPMA Issue Joint Statement Opposing Once-Yearly NHI Price Revision
May 29, 2014
- JPWA Chief Highlights Progress in Single-Product, Single-Price Trading
May 27, 2014
- MTPC, MSD Return to JPMA’s BOD
May 26, 2014
- Yearly NHI Price Revision Not Consistent with Growth Strategy: JPMA Exec
May 23, 2014
- Astellas Chair Nogimori Sworn in as Head of FPMAJ
May 22, 2014
- Dainippon Pres. Tada Elected New Chief of JPMA
May 22, 2014
- Market Share of Generic Drugs Based on New Calculation Method Rose to 44.9% in 3rd Quarter of FY2013: JGA
May 19, 2014
- Quality Control Essential for Preventing Disruptions in Supplies of Generic Drugs; Double-Sourcing Not Enough
May 7, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…